Serum interleukin-1 beta in neonatal sepsis

Area of Science:

• Neonatal immunology
• Infectious diseases
• Biomarker research

Background:

• Sepsis is a life-threatening condition in newborns.
• Interleukin-1 beta (IL-1 beta) is a key inflammatory cytokine.
• Understanding IL-1 beta's role in neonatal sepsis is critical for diagnosis and treatment.

Purpose of the Study:

• To investigate serum IL-1 beta levels in newborn infants with sepsis.
• To explore relationships between IL-1 beta levels, clinical course, and causative microorganisms.
• To compare IL-1 beta levels in septic neonates versus healthy controls.

Main Methods:

• Prospective study design.
• Inclusion of 49 septic and 40 healthy neonates (both mature and premature).
• Measurement of serum IL-1 beta using an immunoradiometric assay.

Main Results:

• Septic neonates had significantly lower median IL-1 beta levels (0.1 pg/ml) than healthy controls (27.9 pg/ml) (p < 0.001).
• Trends towards lower IL-1 beta were observed in infants with shock and non-survivors, though not statistically significant.
• No correlation found between IL-1 beta levels and postnatal age, gestational age, or weight.
• No significant difference in IL-1 beta levels based on Gram-positive versus Gram-negative bacterial infections.

Conclusions:

• Serum IL-1 beta concentration is significantly decreased in both preterm and term neonates with sepsis.
• IL-1 beta may not be a reliable indicator for sepsis severity or specific causative agents in this population.
• Further research is needed to elucidate the role of IL-1 beta in neonatal sepsis pathogenesis.